Compliance and Cumulative Interceptive Rate After Therapy of Peri-implantitis

Peri-Implantitis Clinical Trial

Official title:

Compliance Rate After Therapy of Peri-implantitis: Retrospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05772078
• Other study ID #: 20230208
• Status: Completed
• Start date: July 1, 2023
• Est. completion date: October 30, 2023

Study information

• Verified date: October 2023
• Source: Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Peri-implantitis is a plaque-mediated inflammatory condition featured by progressive bone loss. This entity jeopardizes the longevity of dental implants, thus impacting negatively on the quality of life of patients. Moreover, peri-implantitis is suggested to lead to an increased systemic status of inflammation. This may rise the susceptibility to experience life-threating conditions. Therefore, peri-implant infections must be promptly diagnosed and eliminated.

Aiming at resolving the inflammation, several options are advised to remove the infection. Accordingly, implant removal or therapeutic manoeuvres to stablish a healthy ecosystem in the peri-implant environment have been suggested. While the former proved being more predictable, the later demonstrated being more conservative. Indeed, implant removal is commonly associated with regenerative procedures of the alveolar bone deformity that often demand time and is more costly. Anyways, disease severity, implant expendability for biomechanical reasons or esthetic demand seem to be few of the leading aspects in the decision-making process on maintaining or extracting implant showing peri-implant lesions.

Supportive maintenance care (SPT) was shown to be key in preventing disease recurrence. Nonetheless, the compliance of these patients is often erratic. In fact, it is yet unknown the rate of compliance after therapy. Therefore, the goal of this study is to assess the rate and confounders for compliance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: October 30, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients that underwent treatment of peri-implantitis

• >12 months of follow-up after therapy

• Patients managed in our center

Exclusion Criteria:

• Patients that were managed in other centers

• Patients that have incomplete records

Related Conditions & MeSH terms

• Peri-Implantitis

Intervention

Other:
• Assess compliance rate and demographics
Records to evaluate attendance rate

Locations

Country	Name	City	State
Spain	Centro de Implantologia Cirugia Oral y Maxilofacial	Badajoz

Sponsors (1)

Lead Sponsor	Collaborator
Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cumulative Interceptive Rate	Interventions needed after active therapy to manage peri-implantitis during supportive peri-implant care for erratic and regular compliers	1 to 6 years of follow-upo
Primary	Compliance rate	How many patients are complete compliers	1 to 6 years of follow-up
Secondary	Demographics	Evaluate the patient-related features affecting compliance	1 to 6 years of follow-up